Still reeling from cyberattack, Merck warns some drug supplies may be delayed

Fierce Pharma -------- Merck & Co., one of the victims of the Petya cyberattack last month, has yet to fully restore its manufacturing and R&D operations since they were targeted more than four weeks ago. And though it didn't hit the company's second-quarter results, the global attack and its costs are an unexpected blow to Merck's prospects for the rest of the year. The company said Friday it is confident it can continue to supply its top products, including its highly successful cancer med Keytruda, but warned it may have temporary delays in fulfilling orders for certain other products in some markets. It still is not producing bulk products, but the company said that through significant effort it has been able to keep clinical trials on track. To learn more click on the picture below to read the article.